Developer docs
API playgroundTry for free, no card

Search company profiles

biohit.fi

Full company profile

uuid02mc2zw

Namestring
biohit.fi
Legal namestring
Biohit Oyj
Websiteurl
biohit.fi
Company typeenum
Public
Founded yearint
1988
Descriptiontext

Biohit Oyj is a Finnish biotechnology company headquartered in Helsinki, founded in 1988, and publicly listed on the NASDAQ OMX Helsinki Small Cap exchange under ticker BIOBV. The company is organised around gastrointestinal diagnostics, developing biomarker-based blood tests, point-of-care rapid tests, and laboratory assays built around proprietary biomarker panels. Its core product portfolio includes GastroPanel, a blood-based biomarker test for atrophic gastritis and Helicobacter pylori screening; GastroPanel Quick Test NT, a 20-minute finger-prick rapid test; Acetium, a consumer-facing L-cysteine-based acetaldehyde-binding product positioned for smoking-related and alcohol-related use; ColonView, a FIT-based colorectal cancer screening test; plus ancillary tests for calprotectin, vitamin B12, vitamin D, celiac disease, and H. pylori. The company also supplies monoclonal antibodies for research use, the GP Reader NT benchtop instrument, and GastroSoft interpretation software.

The business model is dual-channel. B2B revenue is generated through the sale of diagnostic test kits, laboratory instruments, and software to hospitals, health centres, and clinical laboratories, supported by clinical validation evidence including the published Oulu study and a publicly cited €42 million estimated Finnish healthcare-savings figure tied to preventive screening. B2C revenue is generated through over-the-counter sale of Acetium capsules and adjacent consumer health products via a proprietary e-commerce storefront. Distribution is executed through wholly-owned subsidiaries in the United Kingdom and Italy combined with a global network of independent distributors. All in-scope medical devices are CE-marked under EU regulatory frameworks, and the company operates under GDPR-compliant data practices.

Operationally, the company participates in industry trade shows including WHX Labs Dubai 2026 and references an annual report for 2025, indicating continued commercial activity but providing no quantitative revenue, headcount, or unit-volume data in the input. Technology infrastructure described is conventional (Google Analytics, Salesforce, Giosg) with no disclosed AI/ML components in either the diagnostic or consumer product lines.

Short descriptiontext

Biohit Oyj is a Finnish biotechnology company developing gastrointestinal diagnostic tests, biomarker-based blood assays, and acetaldehyde-binding consumer health products for healthcare providers, laboratories, and consumers via subsidiaries in Finland, the UK, and Italy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHelsinki, Finland
HQ citystring
Helsinki
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gastrointestinal diagnostics, in vitro diagnostics, medical device manufacturing, biomarker testing kits, acetaldehyde binding products
Industry3 codes
PRIMARYHLAAALAH
Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAIADAD
Gastrointestinal & Digestive Health
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
In Vitro Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Diagnostic Test Kits
TypeOne Time License
Description

Sale of ELISA-based laboratory tests and rapid diagnostic test kits for gastrointestinal conditions including GastroPanel, H. pylori tests, celiac tests, calprotectin, and vitamin D/B12 tests. Sold to healthcare professionals and institutions.

biohithealthcare.com
2Medical Devices (Acetium®)
TypeOne Time License
Description

Sale of Acetium® medical devices (capsules and lozenges) containing L-cysteine for stomach protection and smoking cessation. Distributed through pharmacies, e-commerce (Biohitshop), and supermarkets.

biohithealthcare.com
3Laboratory Instruments
TypeHardware Sales
Description

Sale and supply of laboratory equipment including GP Reader NT for reading diagnostic test results.

biohithealthcare.com
4Monoclonal Antibodies
TypeOne Time License
Description

Sale of research-use monoclonal antibodies covering extracellular matrix components, cytoskeletal proteins, neurotransmitters, and gastric biomarkers.

biohithealthcare.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Acetium® products available for consumer purchase without prescription
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Acetium® capsule (60 capsules) and Acetium® lozenges available over-the-counter at pharmacies across Finland and via Biohitshop online store. Not reimbursed by Kela even with prescription.

biohithealthcare.com
2Diagnostic test kits for healthcare professionals
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Diagnostic kits (GastroPanel, H. pylori tests, Celiac tests, etc.) sold to healthcare institutions and laboratories. Pricing is quote-based and not publicly disclosed on the website.

biohithealthcare.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1GastroPanel®
Description

Diagnostic test panel for gastric mucosal assessment including pepsinogen I, pepsinogen II, gastrin-17, and H. pylori IgG antibodies

biohithealthcare.com
+4 more records
Core offering1 text field

Biohit Oyj develops, manufactures, and sells in vitro diagnostic test kits and laboratory instruments for gastrointestinal and gastric disease detection, including the GastroPanel® multi-biomarker panel for atrophic gastritis and H. pylori screening, rapid point-of-care tests for celiac disease, colorectal cancer (ColonView® FIT), calprotectin, vitamins B12 and D, lactose intolerance, and H. pylori biopsy testing. The company also sells CE-marked Acetium® medical-device capsules and lozenges that use a slow-release L-cysteine formulation to bind carcinogenic acetaldehyde in the stomach or saliva for gastric protection and smoking cessation, plus a research-use monoclonal antibody catalogue and the GastroSoft™ decision-support software and GP Reader NT instrument.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • GastroPanel test showed 92.4% agreement with gastroscopy findings in Oulu University Hospital study (n=522)
+4 more records
Product and service16 records
1GastroPanel® quick test NT
CategoryRapid diagnostic test
Description

Rapid point-of-care test that measures gastric biomarkers (pepsinogen I, pepsinogen II, gastrin-17) and H. pylori IgG antibodies from a finger-prick blood sample to detect atrophic gastritis and H. pylori infection in approximately 20 minutes, intended for healthcare professionals.

2GastroPanel® Unified ELISA
CategoryLaboratory diagnostic test
Description

Enzyme-linked immunosorbent assay (ELISA) based test for comprehensive detection of H. pylori infection and atrophic gastritis using serum biomarkers, used by hospital and reference laboratories.

3GastroSoft™
CategoryDiagnostic software
Description

Decision-support software application for healthcare professionals that analyzes GastroPanel® test results against reference values and generates detailed diagnostic reports, including a flowchart presenting eight different biomarker profiles with interpretations.

4GP Reader NT
CategoryLaboratory instrument
Description

Laboratory instrument designed for reading and analyzing diagnostic test results from Biohit's rapid test portfolio, used in clinical and point-of-care settings.

5BIOHIT Active B12 (HoloTC)
CategoryLaboratory diagnostic test
Description

ELISA-based vitamin test that accurately measures active B12 vitamin (holotranscobalamin) concentration in serum for diagnosis and monitoring of B12 deficiency in laboratory settings.

6BIOHIT Total 25OH Vitamin D
CategoryLaboratory diagnostic test
Description

ELISA test for measuring total 25-hydroxyvitamin D levels in serum for assessment of vitamin D status in laboratory settings.

7BIOHIT Calprotectin
CategoryLaboratory diagnostic test
Description

ELISA-based test for measuring calprotectin levels, a marker of intestinal inflammation used in inflammatory bowel disease diagnostics in clinical laboratories.

8BIOHIT ColonView® quick test (FIT)
CategoryRapid diagnostic test
Description

Fecal immunochemical test (FIT) for detecting occult blood in stool samples, designed for colorectal cancer screening; detects both hemoglobin (Hb) and hemoglobin/haptoglobin complex (Hb/Hp) as indicators of colorectal neoplasia, used in clinical and screening settings.

9BIOHIT Celiac quick test
CategoryRapid diagnostic test
Description

Qualitative point-of-care immunochromatographic in vitro test for detecting tissue transglutaminase antibodies (tTG IgA/IgG/IgM) in whole blood, plasma, or serum samples for celiac disease diagnosis, providing results in 10 minutes.

10BIOHIT Helicobacter pylori UFT300
CategoryRapid diagnostic test
Description

Innovative ureaase-based rapid test for H. pylori detection from biopsy samples during gastroscopy; available in cup and plate versions with positive results in approximately 5 minutes and full confirmation within 5 minutes.

11Helicobacter pylori quick test
CategoryRapid diagnostic test
Description

Rapid diagnostic tool used during gastroscopy to detect H. pylori bacteria directly from gastric tissue biopsy samples; positive results appear within minutes and negative results are confirmed within 30 minutes.

12Lactose Intolerance quick test
CategoryRapid diagnostic test
Description

Rapid test for diagnosing lactase hypolactasia from duodenal biopsy samples during gastroscopy; measures lactase enzyme activity with results in approximately 20 minutes.

13Acetium® lozenge
CategoryConsumer health medical device
Description

Nicotine-free lozenge containing L-cysteine that binds acetaldehyde in saliva; classified as a CE-marked medical device for smoking cessation and acetaldehyde reduction, sold over the counter to consumers.

14Acetium® capsule
CategoryConsumer health medical device
Description

CE-marked medical device containing 100 mg L-cysteine per capsule that binds acetaldehyde in the stomach; designed for individuals with atrophic gastritis, PPI users, or chronic H. pylori infection to reduce carcinogenic acetaldehyde exposure, sold over the counter to consumers.

15BIOHIT FAEX® Sample System
CategoryLaboratory consumable
Description

Sample collection and handling system (FAEX®) for laboratory diagnostic testing workflows, used by clinical laboratories.

16Monoclonal Antibodies (research portfolio)
CategoryResearch reagent
Description

Portfolio of research-use monoclonal antibodies covering human extracellular matrix components, spectrins, cytoskeletal polypeptides, neurotransmitter substances, gastric biomarkers, endothelial cell surface markers, phytoestrogen genistein, and integrins for research and laboratory applications.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeOthers
Description

Wholly-owned subsidiary based in Ellesmere Port, Cheshire, UK. Handles direct sales, distribution, and customer service for Biohit products in the United Kingdom market. Tel: +44 0151 550 4 550.

Strategic tierCoreTypeOthers
Description

Wholly-owned subsidiary based in Pero (Milano), Italy. Handles direct sales, distribution, and customer support for Biohit products in the Italian market. Tel: +39 02 38238113.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Biohit works with authorised distributors globally across multiple regions. The company actively seeks new distribution and licensing partners. An inquiry form on their website covers 15+ product lines for prospective distributors interested in specific regions.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global life science and clinical diagnostics company that manufactures ELISA-based immunoassay kits, quality controls, and diagnostic instruments. Overlaps directly with Biohit's GastroPanel ELISA platform, calprotectin testing, and laboratory instrument portfolio across the same hospital and laboratory customer base.

TypeDirect peer
Description

UK-headquartered point-of-care diagnostics company with a portfolio of rapid tests, ELISA kits, and laboratory analyzers serving gastrointestinal, infectious disease, and women's health. Comparable to Biohit's rapid test kits (H. pylori, celiac, lactose intolerance) and centralized instrument-reader model.

TypeDirect peer
Description

US-based diagnostics company focused on gastrointestinal infectious disease testing, including H. pylori and C. difficile assays. Directly comparable to Biohit's H. pylori UFT300 rapid urease test and broader GI infectious disease diagnostic franchise.

TypeBroad incumbent
Description

Italian-headquartered global IVD company with a specialty immunoassay menu on its LIAISON platforms, including vitamin D and B12 assays that overlap Biohit's Active B12 and Total 25OH Vitamin D ELISA products. A larger established competitor serving the same clinical laboratory channel.

TypeDirect peer
Description

German diagnostics company offering ELISA and rapid tests for gastrointestinal infections (H. pylori, celiac, calprotectin) and clinical chemistry. Closely comparable niche GI diagnostics portfolio with similar customer base of hospitals and clinical laboratories across Europe.

6Aidian (formerly Medix Biochemica)
TypeRegional player
Description

Finnish IVD company specializing in clinical chemistry and immunoassay tests for point-of-care and laboratory use. Comparable as a fellow Finnish diagnostics specialist serving overlapping European clinical laboratory customers with similar ELISA-based test menus.

TypeBroad incumbent
Description

Large US-based diagnostics company offering rapid immunoassays, ELISA systems, and specialty diagnostics including H. pylori testing. Comparable in rapid test technology and clinical diagnostic menu though serving a much broader portfolio of indications and geographies.

8Abbott Diagnostics
TypeBroad incumbent
Description

Global IVD leader with extensive immunoassay menu on ARCHITECT and Alinity platforms including H. pylori, celiac, B12, and vitamin D tests. Represents the scale incumbent whose bundled hospital contracts and broad menu could compete with Biohit's narrower specialty GI offering.

TypeBroad incumbent
Description

World's largest IVD company offering comprehensive immunoassay, clinical chemistry, and molecular diagnostic menus. Comparable through overlapping ELISA-based biomarker testing and laboratory instrument platforms, though as part of a vastly broader diagnostic portfolio.

TypeEmerging player
Description

US diagnostics and women's health company with growing specialty immunoassay menu including gastrointestinal markers. Partial overlap with Biohit's biomarker panel strategy through clinical laboratory testing channels, particularly in women's health-adjacent diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

biohit.fi

In Vitro Diagnosticsbiohit.fi

Biohit Oyj is a Finnish biotechnology company developing gastrointestinal diagnostic tests, biomarker-based blood assays, and acetaldehyde-binding consumer health products for healthcare providers, laboratories, and consumers via subsidiaries in Finland, the UK, and Italy.

What biohit.fi does

Biohit Oyj is a Finnish biotechnology company headquartered in Helsinki, founded in 1988, and publicly listed on the NASDAQ OMX Helsinki Small Cap exchange under ticker BIOBV. The company is organised around gastrointestinal diagnostics, developing biomarker-based blood tests, point-of-care rapid tests, and laboratory assays built around proprietary biomarker panels. Its core product portfolio includes GastroPanel, a blood-based biomarker test for atrophic gastritis and Helicobacter pylori screening; GastroPanel Quick Test NT, a 20-minute finger-prick rapid test; Acetium, a consumer-facing L-cysteine-based acetaldehyde-binding product positioned for smoking-related and alcohol-related use; ColonView, a FIT-based colorectal cancer screening test; plus ancillary tests for calprotectin, vitamin B12, vitamin D, celiac disease, and H. pylori. The company also supplies monoclonal antibodies for research use, the GP Reader NT benchtop instrument, and GastroSoft interpretation software.

The business model is dual-channel. B2B revenue is generated through the sale of diagnostic test kits, laboratory instruments, and software to hospitals, health centres, and clinical laboratories, supported by clinical validation evidence including the published Oulu study and a publicly cited €42 million estimated Finnish healthcare-savings figure tied to preventive screening. B2C revenue is generated through over-the-counter sale of Acetium capsules and adjacent consumer health products via a proprietary e-commerce storefront. Distribution is executed through wholly-owned subsidiaries in the United Kingdom and Italy combined with a global network of independent distributors. All in-scope medical devices are CE-marked under EU regulatory frameworks, and the company operates under GDPR-compliant data practices.

Operationally, the company participates in industry trade shows including WHX Labs Dubai 2026 and references an annual report for 2025, indicating continued commercial activity but providing no quantitative revenue, headcount, or unit-volume data in the input. Technology infrastructure described is conventional (Google Analytics, Salesforce, Giosg) with no disclosed AI/ML components in either the diagnostic or consumer product lines.

biohit.fi firmographics

Firmographics
Name
biohit.fi
Legal name
Biohit Oyj
Website
https://biohit.fi
Company type
Public
Founded year
1988
Operating status
Operating
Headcount range
11–50 employees
Short description
Biohit Oyj is a Finnish biotechnology company developing gastrointestinal diagnostic tests, biomarker-based blood assays, and acetaldehyde-binding consumer health products for healthcare providers, laboratories, and consumers via subsidiaries in Finland, the UK, and Italy.
Ownership category
akta.pro rank

biohit.fi industry classification

Industry
Product category
In Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Pharmaceutical Preparation Manufacturing (325412)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAALAH
Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAIADAD
Gastrointestinal & Digestive Health
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Gastrointestinal diagnostics
  • In vitro diagnostics
  • Medical device manufacturing
  • Biomarker testing kits
  • Acetaldehyde binding products

Where biohit.fi is headquartered

Location

Headquarters

HQ city
Helsinki
HQ country
Finland
HQ region
Europe

Offices3 records

Markets served

biohit.fi business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Test Kits: Sale of ELISA-based laboratory tests and rapid diagnostic test kits for gastrointestinal conditions including GastroPanel, H. pylori tests, celiac tests, calprotectin, and vitamin D/B12 tests. Sold to healthcare professionals and institutions.
  2. Medical Devices (Acetium®): Sale of Acetium® medical devices (capsules and lozenges) containing L-cysteine for stomach protection and smoking cessation. Distributed through pharmacies, e-commerce (Biohitshop), and supermarkets.
  3. Laboratory Instruments: Sale and supply of laboratory equipment including GP Reader NT for reading diagnostic test results.
  4. Monoclonal Antibodies: Sale of research-use monoclonal antibodies covering extracellular matrix components, cytoskeletal proteins, neurotransmitters, and gastric biomarkers.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goAcetium® products available for consumer purchase without prescription
One time/ perpetual licensePay-as-you-goDiagnostic test kits for healthcare professionals

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

biohit.fi product offering

Product offering

Core offering

Biohit Oyj develops, manufactures, and sells in vitro diagnostic test kits and laboratory instruments for gastrointestinal and gastric disease detection, including the GastroPanel® multi-biomarker panel for atrophic gastritis and H. pylori screening, rapid point-of-care tests for celiac disease, colorectal cancer (ColonView® FIT), calprotectin, vitamins B12 and D, lactose intolerance, and H. pylori biopsy testing. The company also sells CE-marked Acetium® medical-device capsules and lozenges that use a slow-release L-cysteine formulation to bind carcinogenic acetaldehyde in the stomach or saliva for gastric protection and smoking cessation, plus a research-use monoclonal antibody catalogue and the GastroSoft™ decision-support software and GP Reader NT instrument.

Differentiator

Problem solved

Functional benefit

Brands

  • GastroPanel®: Diagnostic test panel for gastric mucosal assessment including pepsinogen I, pepsinogen II, gastrin-17, and H. pylori IgG antibodies
  • Acetium®
  • ColonView®
  • GastroSoft™
  • GP Reader NT

Products and services

  • GastroPanel® quick test NT Rapid point-of-care test that measures gastric biomarkers (pepsinogen I, pepsinogen II, gastrin-17) and H. pylori IgG antibodies from a finger-prick blood sample to detect atrophic gastritis and H. pylori infection in approximately 20 minutes, intended for healthcare professionals.
  • GastroPanel® Unified ELISA Enzyme-linked immunosorbent assay (ELISA) based test for comprehensive detection of H. pylori infection and atrophic gastritis using serum biomarkers, used by hospital and reference laboratories.
  • GastroSoft™ Decision-support software application for healthcare professionals that analyzes GastroPanel® test results against reference values and generates detailed diagnostic reports, including a flowchart presenting eight different biomarker profiles with interpretations.
  • GP Reader NT Laboratory instrument designed for reading and analyzing diagnostic test results from Biohit's rapid test portfolio, used in clinical and point-of-care settings.
  • BIOHIT Active B12 (HoloTC) ELISA-based vitamin test that accurately measures active B12 vitamin (holotranscobalamin) concentration in serum for diagnosis and monitoring of B12 deficiency in laboratory settings.
  • BIOHIT Total 25OH Vitamin D ELISA test for measuring total 25-hydroxyvitamin D levels in serum for assessment of vitamin D status in laboratory settings.
  • BIOHIT Calprotectin ELISA-based test for measuring calprotectin levels, a marker of intestinal inflammation used in inflammatory bowel disease diagnostics in clinical laboratories.
  • BIOHIT ColonView® quick test (FIT) Fecal immunochemical test (FIT) for detecting occult blood in stool samples, designed for colorectal cancer screening; detects both hemoglobin (Hb) and hemoglobin/haptoglobin complex (Hb/Hp) as indicators of colorectal neoplasia, used in clinical and screening settings.
  • BIOHIT Celiac quick test Qualitative point-of-care immunochromatographic in vitro test for detecting tissue transglutaminase antibodies (tTG IgA/IgG/IgM) in whole blood, plasma, or serum samples for celiac disease diagnosis, providing results in 10 minutes.
  • BIOHIT Helicobacter pylori UFT300 Innovative ureaase-based rapid test for H. pylori detection from biopsy samples during gastroscopy; available in cup and plate versions with positive results in approximately 5 minutes and full confirmation within 5 minutes.
  • Helicobacter pylori quick test Rapid diagnostic tool used during gastroscopy to detect H. pylori bacteria directly from gastric tissue biopsy samples; positive results appear within minutes and negative results are confirmed within 30 minutes.
  • Lactose Intolerance quick test Rapid test for diagnosing lactase hypolactasia from duodenal biopsy samples during gastroscopy; measures lactase enzyme activity with results in approximately 20 minutes.
  • Acetium® lozenge Nicotine-free lozenge containing L-cysteine that binds acetaldehyde in saliva; classified as a CE-marked medical device for smoking cessation and acetaldehyde reduction, sold over the counter to consumers.
  • Acetium® capsule CE-marked medical device containing 100 mg L-cysteine per capsule that binds acetaldehyde in the stomach; designed for individuals with atrophic gastritis, PPI users, or chronic H. pylori infection to reduce carcinogenic acetaldehyde exposure, sold over the counter to consumers.
  • BIOHIT FAEX® Sample System Sample collection and handling system (FAEX®) for laboratory diagnostic testing workflows, used by clinical laboratories.
  • Monoclonal Antibodies (research portfolio) Portfolio of research-use monoclonal antibodies covering human extracellular matrix components, spectrins, cytoskeletal polypeptides, neurotransmitter substances, gastric biomarkers, endothelial cell surface markers, phytoestrogen genistein, and integrins for research and laboratory applications.

Quantifiable outcome

  • GastroPanel test showed 92.4% agreement with gastroscopy findings in Oulu University Hospital study (n=522)
  • +4 more outcomes

Companies that use biohit.fi

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

biohit.fi technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature6 records

biohit.fi partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Biohit HealthCare Ltd (UK)coreOthersWholly-owned subsidiary based in Ellesmere Port, Cheshire, UK. Handles direct sales, distribution, and customer service for Biohit products in the United Kingdom market. Tel: +44 0151 550 4 550.
  • Biohit HealthCare Srl (Italy)coreOthersWholly-owned subsidiary based in Pero (Milano), Italy. Handles direct sales, distribution, and customer support for Biohit products in the Italian market. Tel: +39 02 38238113.
  • International Distributor/Partner NetworkminorChannel Partner/ Reseller/ DistributorBiohit works with authorised distributors globally across multiple regions. The company actively seeks new distribution and licensing partners. An inquiry form on their website covers 15+ product lines for prospective distributors interested in specific regions.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

biohit.fi competitors and assessment

Company assessment

Direct peers

  • Bio-Rad Laboratories: Global life science and clinical diagnostics company that manufactures ELISA-based immunoassay kits, quality controls, and diagnostic instruments. Overlaps directly with Biohit's GastroPanel ELISA platform, calprotectin testing, and laboratory instrument portfolio across the same hospital and laboratory customer base.
  • EKF Diagnostics: UK-headquartered point-of-care diagnostics company with a portfolio of rapid tests, ELISA kits, and laboratory analyzers serving gastrointestinal, infectious disease, and women's health. Comparable to Biohit's rapid test kits (H. pylori, celiac, lactose intolerance) and centralized instrument-reader model.
  • Meridian Bioscience: US-based diagnostics company focused on gastrointestinal infectious disease testing, including H. pylori and C. difficile assays. Directly comparable to Biohit's H. pylori UFT300 rapid urease test and broader GI infectious disease diagnostic franchise.
  • R-Biopharm: German diagnostics company offering ELISA and rapid tests for gastrointestinal infections (H. pylori, celiac, calprotectin) and clinical chemistry. Closely comparable niche GI diagnostics portfolio with similar customer base of hospitals and clinical laboratories across Europe.

Broad incumbents

  • DiaSorin: Italian-headquartered global IVD company with a specialty immunoassay menu on its LIAISON platforms, including vitamin D and B12 assays that overlap Biohit's Active B12 and Total 25OH Vitamin D ELISA products. A larger established competitor serving the same clinical laboratory channel.
  • QuidelOrtho: Large US-based diagnostics company offering rapid immunoassays, ELISA systems, and specialty diagnostics including H. pylori testing. Comparable in rapid test technology and clinical diagnostic menu though serving a much broader portfolio of indications and geographies.
  • Abbott Diagnostics: Global IVD leader with extensive immunoassay menu on ARCHITECT and Alinity platforms including H. pylori, celiac, B12, and vitamin D tests. Represents the scale incumbent whose bundled hospital contracts and broad menu could compete with Biohit's narrower specialty GI offering.
  • Roche Diagnostics: World's largest IVD company offering comprehensive immunoassay, clinical chemistry, and molecular diagnostic menus. Comparable through overlapping ELISA-based biomarker testing and laboratory instrument platforms, though as part of a vastly broader diagnostic portfolio.

Regional players

  • Aidian (formerly Medix Biochemica): Finnish IVD company specializing in clinical chemistry and immunoassay tests for point-of-care and laboratory use. Comparable as a fellow Finnish diagnostics specialist serving overlapping European clinical laboratory customers with similar ELISA-based test menus.

Emerging players

  • Hologic (Diagnostics): US diagnostics and women's health company with growing specialty immunoassay menu including gastrointestinal markers. Partial overlap with Biohit's biomarker panel strategy through clinical laboratory testing channels, particularly in women's health-adjacent diagnostics.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

biohit.fi social profiles

Digital presence

biohit.fi compliance and trust

Trust signal

Compliance2 records

biohit.fi financial estimates

Financial estimate

Revenue estimate

Valuation estimate

biohit.fi leadership team

Management profile

Number of profiles

Profiles1 record

biohit.fi subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

biohit.fi funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

biohit.fi M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about biohit.fi

What does biohit.fi do?

Biohit Oyj develops, manufactures, and sells in vitro diagnostic test kits and laboratory instruments for gastrointestinal and gastric disease detection, including the GastroPanel® multi-biomarker panel for atrophic gastritis and H. pylori screening, rapid point-of-care tests for celiac disease, colorectal cancer (ColonView® FIT), calprotectin, vitamins B12 and D, lactose intolerance, and H. pylori biopsy testing. The company also sells CE-marked Acetium® medical-device capsules and lozenges that use a slow-release L-cysteine formulation to bind carcinogenic acetaldehyde in the stomach or saliva for gastric protection and smoking cessation, plus a research-use monoclonal antibody catalogue and the GastroSoft™ decision-support software and GP Reader NT instrument.

Is biohit.fi a public or private company?

biohit.fi is a public company. It is classified as public and is currently operating.

When was biohit.fi founded?

biohit.fi was founded in 1988. It employs 11 to 50 people.

Where is biohit.fi based?

biohit.fi is headquartered in Helsinki, Finland, in the Europe region.

How does biohit.fi make money?

Four revenue lines are on record. Diagnostic Test Kits are the primary driver. The others are medical Devices (Acetium®), laboratory Instruments and monoclonal Antibodies.

Who are biohit.fi's main competitors?

Direct peers on record are Bio-Rad Laboratories, EKF Diagnostics, Meridian Bioscience and R-Biopharm. Broad incumbents are DiaSorin, QuidelOrtho, Abbott Diagnostics and Roche Diagnostics. Aidian (formerly Medix Biochemica) is listed as a regional player. Hologic (Diagnostics) is listed as an emerging player.

Does biohit.fi have an API?

No public API is recorded for biohit.fi.

What industry is biohit.fi in?

biohit.fi's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAAALAH, Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing), with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
KauppalehtiBiohitin hallituksen puheenjohtaja eroaa tehtävästäänKari Syrjänen resigned as chairman of Biohit, citing personal reasons. Kalle Härkösen, who has served on the board since 2022, was elected to replace him. Biohit develops products for disease diagnosis and prevention.news.cision.comBIOHIT GROUP FINANCIAL STATEMENT RELEASE 2021Biohit Oyj reported 2021 revenue of EUR 9.4 million, up 31.4% year-over-year, with operative EBITDA of EUR 0.5 million. The company posted a net loss of EUR 1.5 million, driven by patent amortization, and expects 2022 profitability to improve. The board proposed no dividend for 2021.GlobeNewswireTREATMENT RECOMMENDATION IN RUSSIA: GastroPanel®The Russian Ministry of Health published a recommendation for early detection of gastrointestinal diseases, endorsing a four-biomarker panel (pepsinogen I, pepsinogen II, gastrin-17, and Helicobacter pylori antibody) for low-risk patients before gastroscopy. Biohit Oyj's GastroPanel is the only such panel on the market, and CEO Semi Korpela said it can identify patients needing gastroscopy, saving costs and offering a patient-friendly blood test.GlobeNewswireBIOHIT GROUP HALF YEAR FINANCIAL REPORT 2019Biohit Oyj reported H1 2019 net sales of EUR 5.0 million, up 1% year-over-year, with operative EBITDA of EUR 0.4 million. CEO Semi Korpela said China's GastroPanel re-registration delay reduced sales, but raw material deliveries improved profitability. The company expects moderate 2019 growth, not above EUR 11 million.GlobeNewswireBiohit Oyj B-shares Subscribed with Stock Options I 2013Biohit Oyj subscribed 88,552 new B-shares under its stock options I 2013 scheme between February and May 2019, entered into the Trade Register on June 12, 2019. The subscription price was EUR 2.2766 per share, and public trading on NASDAQ Helsinki began June 13, 2019.GlobeNewswireBiohit Plc - Managers' transactions - SöderströmBiohit's senior manager Daniela Söderström subscribed to 25,000 shares on May 29, 2019, at a weighted average price of 2.2766 EUR. The transaction was linked to the company's stock option programme and was filed as an initial notification.GlobeNewswireDecisions of the Annual General Meeting of Biohit OyjBiohit Oyj's AGM on April 24, 2019 approved financial statements and discharged directors from 2018 liability. It resolved no dividend for the period ended December 31, 2018, elected six board members, and chose PricewaterhouseCoopers as auditor. All decisions were unanimous.GlobeNewswireAcetium® lozenge for smoking intervention will shortly be distributed in Italy within Difar Consumer Care® product divisionBiohit Oyj and Difar Distribuzione signed an agreement to distribute Acetium lozenge in Italy. The lozenge contains L-cysteine that binds up to 90% of smoke-derived acetaldehyde, a carcinogen, and is free of nicotine and side effects. The partnership aims to increase availability for smokers seeking to quit.GlobeNewswireAcetium® lozenge for smoking intervention will be available in Thailand during the year 2019Biohit Oyj and Precision Health Co., Ltd. signed an agreement to distribute Acetium lozenge in Thailand, with the product in FDA registration. The lozenge contains L-cysteine to remove up to 90% of acetaldehyde from saliva, and Precision Health will invest in its registration and promotion.GlobeNewswireNotice of Biohit Oyj’s Annual General MeetingBiohit Oyj will hold its Annual General Meeting on April 24, 2019, in Helsinki. The board proposes no dividend, and shareholders have proposed confirming six board members and electing PricewaterhouseCoopers as auditor. The meeting will also address financial statements and auditor remuneration.